🔔Stock Alerts via Telegram — Free for All Users

Stock Comparison

ABBV vs VRTX

AbbVie Inc vs Vertex Pharmaceuticals Inc

The Verdict

VRTX takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed
Winner
VRTX

Vertex Pharmaceuticals Inc

4.7

out of 10

Proceed with Caution

Head-to-Head

$403.8B

Market Cap

$109.0B
171.8

P/E Ratio

27.6
N/A

Profit Margin

32.9%
N/A

Return on Equity

22.7%
N/A

Debt-to-Equity

0.0
Moderate

Overall Risk

Moderate
0.1

DVR Score

4.7

The Deep Dive

ABBV0.1/10

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

Full ABBV Analysis
VRTX4.7/10

Vertex Pharmaceuticals maintains its strong market position in Cystic Fibrosis and continues to advance a robust pipeline in high-growth areas like gene editing (Casgevy), non-opioid pain (VX-548), and Type 1 Diabetes. Recent FDA approval for expanded ALYFTREK use and solid Q4 2025 financials (revenue beat, strong EPS growth) underscore its operational strength and profitability. However, for a co...

Full VRTX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.